Serine protease molecules and therapies

Patent metadata

Field	Value
Publication number	US-9951325-B2
Application number	US-201414322485-A
Country	US
Kind code	B2
Filing date	Jul 2, 2014
Priority date	Oct 4, 2012
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

First claim

What is claimed is:

1. A cell-targeting polypeptide construct comprising, from N- to C-terminus:
(a) a truncated serine protease having an IIGG, IVGG or ILGG at its N-terminus, the truncated serine protease having an amino acid sequence at least 95% identical to a SEQ ID NO: 1, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57or SEQ ID NO: 58;
(b) an antibody heavy chain constant (Fc) domain; and
(c) a cell-targeting scFv antibody domain.

2. The cell-targeting construct of claim 1 , wherein the Fc domain is a human IgG Fc domain.

3. The cell-targeting construct of claim 2 , wherein the Fc domain is a human IgG 1 Fc domain.

4. The cell-targeting construct of claim 1 , wherein the scFv domain binds to a cancer cell antigen.

5. The cell-targeting construct of claim 1 , wherein the scFv domain binds to GP240, 5T4, HER1, HER2, CD-33, CD-38, VEGFR-1, VEGFR-2, CEA, FGFR3, IGFBP2, Fn14, TNFRSF12A or IGF-1R.

6. The cell-targeting construct of claim 1 , wherein the scFv domain comprises the 4D5, HMEL, IT4 or FRP5 scFv.

7. The cell-targeting construct of claim 1 , wherein the truncated serine protease is 95% identical to a truncated serine protease selected from the group consisting of granzyme B (SEQ ID NO: 1), granzyme A (SEQ ID NO: 46), granzyme H (SEQ ID NO: 47), granzyme K (SEQ ID NO: 48), granzyme M (SEQ ID NO: 49).

8. The cell-targeting construct of claim 7 , wherein the truncated serine protease is 95% identical to Granzyme B (GrB) polypeptide (SEQ ID NO: 1).

9. The cell-targeting construct of claim 8 , wherein the GrB polypeptide comprises an amino acid substitution or deletion at the position corresponding to Cys 210.

10. The cell-targeting construct of claim 1 , further comprising a linker sequence between the truncated serine protease and the antibody heavy chain Fc domain and/or between the antibody heavy chain Fc domain and the cell-targeting scFv antibody domain.

11. The cell-targeting construct of claim 10 , wherein the linker sequence is a protease-cleavable linker.

12. A cell targeting complex comprising a first and second cell targeting construct, each cell targeting construct in accordance with claim 1 , wherein the first and second constructs are linked by disulfide bonds between the antibody heavy chain Fc domain of the first construct and the antibody heavy chain Fc domain of the second construct.

13. A composition comprising a cell-targeting construct according to claim 1 in a pharmaceutically acceptable carrier.

14. The cell-targeting construct of claim 5 , wherein the scFv domain binds to TNFRSF12A.

15. The cell-targeting construct of claim 14 , wherein the scFv domain comprises the IT 4 scFv.

16. The cell-targeting construct of claim 15 , wherein the truncated serine protease comprises a granzyme B coding sequence at least 95% identical SEQ ID NO: 1.

17. The cell-targeting construct of claim 16 , wherein the truncated serine protease comprises a granzyme B coding sequence identical to SEQ ID NO: 1.

Assignees

• Res Found Dev

Inventors

• Rosenblum Michael G
• Mohamedali Khalid Amanali
• Cheung Lawrence H

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P13/08

  of the prostate · CPC title